Evolving concepts in the diagnosis, pathogenesis and treatment of autoimmune hepatitis

Minerva Gastroenterologica e Dietologica

Volumn 53, Issue 1, 2007, Pages 43-78

  Czaja, A J ^a  

^a MAYO CLINIC   (United States)

Author keywords

Hepatitis, autoimmune, diagnosis; Hepatitis, autoimmune, pathology; Hepatitis, autoimmune, therapy

Indexed keywords

AUTOANTIBODY; AZATHIOPRINE; BUDESONIDE; CYCLOSPORIN; CYTOKINE; LIVER ANTIGEN; MERCAPTOPURINE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; TACROLIMUS;

ALLELE; AUTOIMMUNE HEPATITIS; CYTOPENIA; DNA POLYMORPHISM; DRUG MECHANISM; GEOGRAPHIC DISTRIBUTION; HUMAN; LIVER CELL; LYMPHOCYTE; NATURAL KILLER T CELL; PATHOGENESIS; REVIEW;

HEPATITIS, AUTOIMMUNE; HUMANS;

EID: 34250832713     PISSN: 00264776     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (314)

1. Krawitt EL. Autoimmune hepatitis. N Engl J Med 2006;354:54-66.
2. Manns MP, Vogel A. Autoimmune hepatitis, from mechanisms to therapy. Hepatology 2006;43 Suppl 1:S132-44.
3. Czaja AJ, Carpenter HA. Validation of a scoring system for the diagnosis of autoimmune hepatitis. Dig Dis Sci 1996;41:305-14.
4. Kessler WR, Cummings OW, Eckert G, Chalasani N, Lumeng L, Kwo PY. Fulminant hepatic failure as the initial presentation of acute autoimmune hepatitis. Clin Gastroenterol Hepatol 2004;2:625-31.
5. Roberts SK, Therneau T, Czaja AJ. Prognosis of histological cirrhosis in type 1 autoimmune hepatitis. Gastroenterology 1996;110:848-57.
6. Boberg KM, Aadland E, Jahnsen J, Raknerud N, Stiris M, Bell H. Incidence and prevalence of primary biliary cirrhosis, primary sclerosing cholangitis, and autoimmune hepatitis in a Norwegian population. Scand J Gastroenterol 1998;33:99-103.
7. Boberg KM. Prevalence and epidemiology of autoimmune hepatitis. Clin Liver Dis 2002;6:635-47.
8. Jacobson DL, Gange SJ, Rose NR, Graham NM. Epidemiology and estimated population burden of selected autoimmune diseases in the United States. Clin Immunol Immunopath 1997;84:223-43.
9. Seaberg EC, Belle SH, Beringer KC, Schivins JL, Detre KM. Liver transplantation in the United States from 1987-1998: updated results from the Pitt-UNOS liver transplant registry. In: Cecka JM, Terasaki PI, editors. Clinical Transplants 1998. Los Angeles: UCLA Tissue Typing Laboratories; 1999. p. 17-37.
10. Czaja AJ, Freese DK. Diagnosis and treatment of autoimmune hepatitis. Hepatology 2002;36:479-97.
11. Floreani A, Niro G, Rosa Rizzotto E, Antoniazzi S, Ferrara F, Carderi I et al. Type 1 autoimmune hepatitis: clinical course and outcome in an Italian multicentre study. Aliment Pharmacol Ther 2006;24:1051-7.
12. Czaja AJ, Ammon HV, Summerskill WHJ. Clinical features and prognosis of severe chronic active liver disease (CALD) after corticosteroid-induced remission. Gastroenterology 1980;78:518-23.
13. Czaja AJ, Ludwig J, Baggenstoss AH, Wolf A. Corticosteroid-treated chronic active hepatitis in remission. Uncertain prognosis of chronic persistent hepatitis. N Engl J Med 1981;304:5-9.
14. Hegarty JE, Nouri-Aria KT, Portmann B, Eddleston ALWF, Williams R. Relapse following treatment withdrawal in patients with autoimmune chronic active hepatitis. Hepatology 1983;3:685-9.
15. Czaja AJ, Carpenter HA. Histological features associated with relapse after corticosteroid withdrawal in type 1 autoimmune hepatitis. Liver Int 2003;23:116-23.
16. Czaja AJ. Drug therapy in the management of type 1 autoimmune hepatitis. Drugs 1999;57:49-68.
17. Czaja AJ. Emerging treatments for autoimmune hepatitis. Curr Drug Targets Inflamm Allergy 2002;1:317-26.
18. Czaja AJ. Treatment of autoimmune hepatitis. Semin Liver Dis 2002;22:365-77.
19. Czaja AJ, Bianchi FB, Carpenter HA, Krawitt EL, Lohse AW, Manns MP et al. Treatment challenges and investigational opportunities in autoimmune hepatitis. Hepatology 2005;41:207-15.
20. Montano-Loza AJ, Czaja AJ. Current therapy of autoimmune hepatitis. Nature Clin Pract Gastroenterol Hepatol. In press.
21. Alvarez F, Berg PA, Bianchi FB, Bianchi L, Burroughs AK, Cancado EL et al. International Autoimmune Hepatitis Group report: review of criteria for diagnosis of autoimmune hepatitis. J Hepatol 1999;31:929-38.
22. Talwalkar JA, Keach JC, Angulo P, Lindor KD. Overlap of autoimmune hepatitis and primary biliary cirrhosis: an evaluation of a modified scoring system. Am J Gastroenterol 2002;97:1191-7.
23. Dickson RC, Gaffey MJ, Ishitani MB, Roarty TP, Driscoll CJ, Caldwell SH. The international autoimmune hepatitis score in chronic hepatitis C. J Viral Hepat 1997;4: 121-8.
24. Boberg KM, Fausa O, Haaland T, Holter E, Mellbye OJ, Spurkland A et al. Features of autoimmune hepatitis in primary sclerosing cholangitis: an evaluation of 114 primary sclerosing cholangitis patients according to a scoring system for the diagnosis of autoimmune hepatitis. Hepatology 1996;23:1369-76.
25. Baggenstoss AH, Soloway RD, Summerskill WHJ, Elveback LR, Schoenfield LJ. Chronic active liver disease. The range of histologic lesions, their response to treatment, and evolution. Hum Pathol 1972;3:183-98.
26. Schalm SW, Korman MG, Summerskill WHJ, Czaja AJ, Baggenstoss AH. Severe chronic active liver disease. Prognostic significance of initial morphologic patterns. Am J Dig Dis 1977;22:973-80.
27. Cooksley WGE, Bradbear RA, Robinson W, Harrison M, Halliday JW, Powell LW et al. The prognosis of chronic active hepatitis without cirrhosis in relation to bridging necrosis. Hepatology 1986;6:345-8.
28. Czaja AJ, Carpenter HA. Sensitivity, specificity and predictability of biopsy interpretations in chronic hepatitis. Gastroenterology 1993;105:1824-32.
29. Scheuer PJ, Ashrafzadeh P, Sherlock S, Brown D, Dusheiko GM. The pathology of hepatitis C. Hepatology 1992;15:567-71.
30. Bach N, Thung SN, Schaffner F. The histological features of chronic hepatitis C and autoimmune chronic hepatitis: a comparative analysis. Hepatology 1992;15: 572-7.
31. Czaja AJ, Carpenter HA. Histological findings in chronic hepatitis C with autoimmune features. Hepatology 1997;26:459-66.
32. Pratt DS, Fawaz KA, Rabson A, Dellelis R, Kaplan MM. A novel histological lesion in glucocorticoid-responsive chronic hepatitis. Gastroenterology 1997;113:664-8.
33. Abe M, Hiasa Y, Masumoto T, Kumagi T, Akbar SM, Ninomiya T et al. Clinical characteristics of autoimmune hepatitis with histological features of acute hepatitis. Hepatol Res 2001;21:213-9.
34. Singh R, Nair S, Farr G, Mason A, Perrillo R. Acute autoimmune hepatitis presenting with centrizonal liver disease: case report and review of the literature. Am J Gastroenterol 2002;97:2670-3.
35. Okano N, Yamamoto K, Sakaguchi K, Miyake Y, Shimada N, Hakoda T et al. Clinicopathological features of acute-onset autoimmune hepatitis. Hepatol Res 2003;25:263-70.
36. Misdraji J, Thiim M, Graeme-Cook FM. Autoimmune hepatitis with centrilobular necrosis. Am J Surg Pathol 2004;28:471-8.
37. Kanda T, Yokosuka O, Hirasawa Y, Imazeki F, Nagao K, Suzuki Y et al. Acute-onset autoimmune hepatitis resembling acute hepatitis: a case report and review of reported cases. Hepatogastroenterology 2005;52:1233-5.
38. Ludwig J, Czaja AJ, Dickson ER, LaRusso NF, Wiesner RH. Manifestations of nonsuppurative cholangitis in chronic hepatobiliary disease: morphologic spectrum, clinical correlations and terminology. Liver 1984;4:105-16.
39. Czaja AJ, Carpenter HA, Santrach PJ, Moore SB. Autoimmune cholangitis within the spectrum of autoimmune liver disease. Hepatology 2000;31:1231-8.
40. Czaja AJ, Carpenter HA. Autoimmune hepatitis with incidental histologic features of bile duct injury. Hepatology 2001;34:659-65.
41. Czaja AJ, Muratori P, Muratori L, Carpenter HA, Bianchi FB. Diagnostic and therapeutic implications of bile duct injury in autoimmune hepatitis. Liver Int 2004;24:322-9.
42. Davis GL, Czaja AJ, Baggenstoss AH, Taswell HF. Prognostic and therapeutic implications of extreme serum aminotransferase elevation in chronic active hepatitis. Mayo Clin Proc 1982;57:303-9.
43. Crapper RM, Bhathal PS, Mackay IR, Frazer IH. "Acute" autoimmune hepatitis. Digestion 1986;34:216-25.
44. Amontree JS, Stuart TD, Bredfeldt JE. Autoimmune chronic active hepatitis masquerading as acute hepatitis. J Clin Gastroenterol 1989;11:303-7.
45. Maggiore G, Porta G, Bernard O, Hadchouel M, Alvarez F, Homberg JC et al. Autoimmune hepatitis with initial presentation as acute hepatic failure in young children. J Pediatr 1990;116:280-2.
46. Porta G, Da Costa Gayotto LC, Alvarez F. Anti-liver-kidney microsome antibody-positive autoimmune hepatitis presenting as fulminant liver failure. J Pediatr Gastroenterol Nutr 1990;11:138-40.
47. Nikias GA, Batts KP, Czaja AT. The nature and prognostic implications of autoimmune hepatitis with an acute presentation. J Hepatol 1994;21:866-71.
48. Burgart LJ, Batts KP, Ludwig J, Nikias GA, Czaja AJ. Recent onset autoimmune hepatitis: biopsy findings and clinical correlations. Am J Surg Pathol 1995; 19:699-708.
49. Herzog D, Rasquin-Weber AM, Debray D, Alvarez F. Subfulminant hepatic failure in autoimmune hepatitis type 1: an unusual form of presentation. J Hepatol 1997;27:578-82.
50. Viruet EJ, Torres EA. Steroid treatment in fulminant hepatic failure secondary to autoimmune hepatitis. P R Health Sci J 1998;17:297-300.
51. Ichai P, Duclos-Vallee JC, Guettier C, Ben Hamida S, Antonini T, Delvart V et al. Usefulness of corticosteroids for the treatment of severe and fulminant forms of autoimmune hepatitis. Liver Transpl. In press.
52. Czaja AJ. Corticosteroids or not in severe acute or fulminant autoimmune hepatitis: therapeutic brinksmanship and the point beyond salvation. Liver Transpl. In press.
53. Gonazalez-Koch A, Czaja AJ, Carpenter HA, Roberts SK, Charlton MR, Porayko MK et al. Recurrent autoimmune hepatitis after orthotopic liver transplantation. Liver Transpl 2001;7:302-10.
54. Czaja AJ. Autoimmune hepatitis after liver transplantation and other lessons of self-intolerance. Liver Transpl 2002;8:505-13.
55. Kerkar N, Hadzic N, Davies ET, Portmann B, Donaldson PT, Rela M et al. De-novo autoimmune hepatitis after liver transplantation. Lancet 1998;353:409-13.
56. Heneghan MA, Portmann BC, Norris SM, Williams R, Muiesan P, Rela M et al. Graft dysfunction mimicking autoimmune hepatitis following liver transplantation in adults. Hepatology 2001;34:464-70.
57. Czaja AJ, Rakela J, Ludwig J. Features reflective of early prognosis in corticosteroid-treated severe autoimmune chronic active hepatitis. Gastroenterology 1988;95:448-53.
58. Kogan J, Safadi R, Ashur Y, Shouval D, Ilan Y. Prognosis of symptomatic versus asymptomatic autoimmune hepatitis. A study of 68 patients. J Clin Gastroenterol 2002;35:75-81.
59. Feld JJ, Dinh H, Arenovich T, Marcus VA, Wanless IR, Heathcote EJ. Autoimmune hepatitis: effect of symptoms and cirrhosis on natural history and outcome. Hepatology 2005;42:53-62.
60. Lim KN, Casanova RL, Boyer TD, Bruno CJ. Autoimmune hepatitis in African Americans: presenting features and responses to therapy. Am J Gastroenterol 2001;96:3390-4.
61. Hurlburt KJ, McMahon BJ, Deubner H, Hsu-Trawinski B, Williams JL, Kowdley KV. Prevalence of autoimmune liver disease in Alaska natives. Am J Gastroenterol 2002;97:2402-7.
62. Zolfino T, Heneghan MA, Norris S, Harrison PM, Portmann BC, McFarlane IG. Characteristics of autoimmune hepatitis in patients who are not of European Caucasoid ethnic origin. Gut 2002;50:713-7.
63. Nakamura K, Yoneda M, Yokohama S, Tamori K, Sato Y, Aso K et al. Efficacy of ursodeoxycholic acid in Japanese patients with type 1 autoimmune hepatitis. J Gastroenterol Hepatol 1998;13:490-5.
64. Czaja AJ, Souto EO, Bittencourt PL, Cancado ELR, Porto G, Goldberg AC et al. Clinical distinctions and pathogenic implications of type 1 autoimmune hepatitis in Brazil and the United States. J Hepatol 2002;37:302-8.
65. D'Souza R, Sinnott P, Glynn MJ, Sabin CA, Foster GR. An unusual form of autoimmune hepatitis in young Somalian men. Liver Int 2005;25:325-30.
66. Gregorio GV, Portmann B, Reid F, Donaldson PT, Doherty DG, McCartney M et al. Autoimmune hepatitis in childhood. A 20 year survey. Hepatology 1997;25:541-7.
67. Gregorio GV, Portmann B, Karani J, Harrison P, Donaldson PT, Vergani D et al. Autoimmune hepatitis/sclerosing cholangitis overlap syndrome in childhood: a 16-year prospective study. Hepatology 2001;33:544-53.
68. Schramm C, Kanzler S, Meyer zum Buschenfelde KH, Galle PR, Lohse AW. Autoimmune hepatitis in the elderly. Am J Gastroenterol 2001:96:1587-91.
69. Verslype C, George C, Buchel E, Nevens F, Van Steenbergen W, Fevery J. Diagnosis and treatment of autoimmune hepatitis at age 65 and older. Aliment Pharmacol Ther 2005;21:695-9.
70. Granito A, Muratori L, Pappas G, Muratori P, Ferri S, Cassani F et al. Clinical features of type 1 autoimmune hepatitis in elderly Italian patients. Aliment Pharmacol Ther 2005; 21:1273-7.
71. Al-Chalabi T, Boccato S, Portmann BC, McFarlane IG, Heneghan MA. Autoimmune hepatitis (AIH) in the elderly: a systematic retrospective analysis of a large group of consecutive patients with definite AIH followed at a tertiary referral center. J Hepatol 2006;45:575-83.
72. Miyake T, Miyaoka H, Abe M, Furukawa S, Shigematsu S, Furukawa E et al. Clinical characteristics of autoimmune hepatitis in older aged patients. Hepatol Res 2006;36:139-42.
73. Czaja AJ, Carpenter HA. Distinctive clinical phenotype and treatment outcome of type 1 autoimmune hepatitis in the elderly. Hepatology 2006;43:532-8.
74. Ben-Yehuda A, Weksler ME. Immune senescence: mechanisms and clinical implications. Cancer Invest 1992;10:525-31.
75. Currie MS. Immunosenescence. Compr Ther 1992;18: 26-34.
76. Paganelli R, Quinti I, Fagiolo U, Cossarizza A, Ortolani C, Guerra E et al. Changes in circulating B cells and immunoglobulin classes and subclasses in a healthy aged population. Clin Exp Immunol 1992;90:351-4.
77. Schwab R, Russo C, Weksler ME. Altered major histocompatibility complex-restricted antigen recognition by T cells from elderly humans. Eur J Immunol 1992;22:2989-93.
78. Czaja AJ, Davis GL, Ludwig J, Baggenstoss AH, Taswell HF. Autoimmune features as determinants of prognosis in steroid-treated chronic active hepatitis of uncertain etiology. Gastroenterology 1983;85:713-7.
79. Czaja AJ, Carpenter HA, Santrach PJ, Moore SB, Taswell HF, Homburger HA. Evidence against hepatitis viruses as important causes of severe autoimmune hepatitis in the United States. J Hepatol 1993;18:342-52.
80. Perdigoto R, Carpenter HA, Czaja AJ. Frequency and significance of chronic ulcerative colitis in severe corticosteroid-treated autoimmune hepatitis. J Hepatology 1992;14:325-31.
81. Aaltonen J, Borses P, Sandkuijl L, Perheentupa J, Peltonen L. An autosomal locus causing autoimmune disease: autoimmune polyglandular disease type 1 assigned to chromosome 21. Nat Genet 1994;8:83-7.
82. Clemente MG, Obermayer-Straub P, Meloni A, Strassburg CP, Arangino V, Tukey RH et al. Cytochrome P450 1A2 is a hepatic autoantigen in autoimmune polyglandular syndrome type 1. J Clin Endocrinol Metab 1997;82:1353-61.
83. Obermayer-Straub P, Perheentupa J, Braun S, Kayser A, Barut A, Loges S et al. Hepatic autoantigens in patients with autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy. Gastroenterology 2001;121: 668-77.
84. Nagamine K, Peterson P, Scott HS, Kudoh J, Minoshima S, Heino M et al. Positional cloning of the APECED gene. Nat Genet 1997;17:393-8.
85. Lankisch TO, Strassburg CP, Debray D, Manns MP, Jacquemin E. Detection of autoimmune regulator gene mutations in children with type 2 autoimmune hepatitis and extrahepatic immune-mediated diseases. J Pediatr 2005;146:839-42.
86. Vogel A, Liermann H, Harms A, Strassburg CP, Manns MP, Obermayer-Straub P. Autoimmune regulator AIRE: evidence for genetic differences between autoimmune hepatitis and hepatitis as part of the autoimmune polyglandular syndrome type 1. Hepatology 2001;33:1047-52.
87. Boe AS, Knappskog PM, Myhre AG, Sorheim JI, Husebye ES. Mutational analysis of the autoimmune regulator (AIRE) gene in sporadic autoimmune Addison's disease can reveal patients with unidentified autoimmune polyglandular syndrome type 1. Eur J Endocrinol 2002;146:519-22.
88. Volta U, De Franceschi L, Molinaro N, Cassani F, Muratori L, Lenzi M et al. Frequency and significance of anti-gliadin and anti-endomysial antibodies in autoimmune hepatitis. Dig Dis Sci 1998;43:2190-5.
89. Abdo A, Meddings J, Swain M. Liver abnormalities in celiac disease. Clin Gastroenterol Hepatol 2004;2:107-12.
90. Bardella MT, Fraquelli M, Quatrini M, Molteni N, Bianchi P, Conti D. Prevalence of hypertransaminasemia in adult celiac patients and effect of gluten-free diet. Hepatology 1995;22:833-6.
91. Kaukinen K, Halme L, Collin P, Farkkila M, Maki M, Vehmanen P et al. Celiac disease in patients with severe liver disease: gluten-free diet may reverse hepatic failure. Gastroenterology 2002;122:881-8.
92. Sedlack RE, Smyrk TC, Czaja AJ, Talwalkar JA. Celiac-disease-associated autoimmune cholangitis. Am J Gastroenterol 2002;97:3196-8.
93. Volta U, Rodrigo L, Granito A, Petrolinin N, Muratori P, Muratori L et al. Celiac disease in autoimmune cholestatic liver disorders. Am J Gastroenterol 2002:97:2609-13.
94. Vecchi M, Folli C, Donato MF, Formenti S, Arosio E, De Franchis R. High rate of positive anti-tissue trans-glutaminase antibodies in chronic liver disease. Role of liver decompensation and of the antigen source. Scand J Gastroenterol 2003;38:50-4.
95. Greenberg CS, Birckbichler PL, Rice RH. Transglutaminases: multifactorial cross-linking enzymes that stabilize tissues. FASEB J 1991;5:3071-7.
96. Leon F, Camarero C, Pena R, Eiras P, Sanchez L, Baragano M et al. Anti-transglutaminase IgA ELISA: clinical potential and drawbacks in celiac disease diagnosis. Scand J Gastroenterol 2001;36:849-53.
97. Biagi F, Pezzimenti D, Campanella J, Vadacca GB, Corazzo GR. Endomysial and tissue transglutaminase antibodies in coeliac sera: a comparison not influenced by previous serological testing. Scand J Gastroenterol 2001;35:955-8.
98. Green PH, Barry M, Matsutani M. Serologic tests for celiac disease. Gastroenterology 2003;124:585-6.
99. Czaja AJ. Autoantibodies in autoimmune liver disease. Adv Clin Chem 2005;40:127-64.
100. Czaja AJ. Behavior and significance of autoantibodies in type 1 autoimmune hepatitis. J Hepatol 1999:30:394-401.
101. Czaja AJ, Nishioka M, Morshed SA, Hachiya T. Patterns of nuclear immunofluorescence and reactivities to recombinant nuclear antigens in autoimmune hepatitis. Gastroenterology 1994;107:200-7.
102. Czaja AJ, Cassani F, Cataleta M, Valentini P, Bianchi FB. Antinuclear antibodies and patterns of nuclear immunofluorescence in type 1 autoimmune hepatitis. Dig Dis Sci 1997;42:1688-96.
103. Zuchner D, Sternsdorf T, Szostecki C, Heathcote EJ, Cauch-Dudek K, Will H. Prevalence, kinetics, and therapeutic modulation of autoantibodies against Sp100 and promyelocytic leukemia protein in a large cohort of patients with primary biliary cirrhosis. Hepatology 1997;26:1123-30.
104. Szostecki C, Guldner HH, Will H. Autoantibodies against "nuclear dots" in primary biliary cirrhosis. Semin Liver Dis 1997;17:71-8.
105. Muratori P, Muratori L, Cassani F, Terlizzi P, Lenzi M, Rodrigo L et al. Anti-multiple nuclear dots (anti-MND) and anti-Sp100 antibodies in hepatic and rheumatological diseases. Clin Exp Immunol 2002;127:172-5.
106. Muratori P, Muratori L, Ferrari R, Cassani F, Bianchi G, Lenzi M et al. Characterization and clinical impact of antinuclear antibodies in primary biliary cirrhosis. Am J Gastroenterol 2003;98:431-7.
107. Courvalin JC, Lassoued K, Bartnik E, Blobel G, Wozniak RW. The 210-kD nuclear envelope polypeptide recognized by human autoantibodies in primary biliary cirrhosis is the major glycoprotein of the nuclear pore. J Clin Invest 1990;86:279-85.
108. Courvalin JC, Lassoued K, Worman HJ, Blobel G. Identification and characterization of autoantibodies against the nuclear envelope lamin B receptor from patients with primary biliary cirrhosis. J Exp Med 1990;172:961-7.
109. Lassoued K, Brenard R, Degos F, Courvalin J-C, Andre C, Danon F et al. Antinuclear antibodies directed to a 200-kilodalton polypeptide of the nuclear envelope in primary biliary cirrhosis. Gastroenterology 1990;99:181-6.
110. Lin F, Noyer CM, Ye Q, Courvalin JC, Worman HJ. Autoantibodies from patients with primary biliary cirrhosis recognize a region within the nucleoplasmic domain of inner nuclear membrane protein LBR. Hepatology 1996;23:57-61.
111. Courvalin JC, Worman HJ. Nuclear envelope protein autoantibodies in primary biliary cirrhosis. Semin Liver Dis 1997;17:79-90.
112. Invernizzi P, Podda M, Battrezzati PM, Crosignani A, Zuin M, Hitchman E et al. Autoantibodies against nuclear pore complexes are associated with more active and severe liver disease in primary biliary cirrhosis. J Hepatol 2001;34:366-72.
113. Alvarez F, Bernard O, Homberg JC, Kreibich G. Anti-liver-kidney microsome antibody recognizes a 50,000 molecular weight protein of the endoplasmic reticulum. J Exp Med 1985;161:1231-6.
114. Gueguen M, Meunier-Rotival M, Bernard O, Alvarez F. Anti-liver kidney microsome antibody recognizes a cytochrome P450 from the IID subfamily. J Exp Med 1988;168:801-6.
115. Gueguen M, Yamamoto AM, Bernard O, Alvarez F. Anti-liver kidney microsome antibody type 1 recognizes human cytochrome P450 db1. Biochem Biophys Res Comm 1989;159:542-7.
116. Codoner-Franch P, Paradis K, Gueguen M, Bernard O, Costesec AA, Alvarez F. A new antigen recognized by anti-liver-kidney-microsome antibody (LKMA). Clin Exp Immunol 1989;75:354-8.
117. Manns MP, Johnson EF, Griffin KJ, Tan EM, Sullivan KF. Major antigen of liver kidney microsomal autoantibodies in idiopathic autoimmune hepatitis is cytochrome P450db1. J Clin Invest 1989;83:1066-72.
118. Manns MP, Griffin KJ, Sullivan KF, Johnson EF. LKM-1 autoantibodies recognize a short linear sequence in P450IID6, a cytochrome P-450 monooxygenase. J Clin Invest 1991;88:1370-8.
119. Gueguen M, Boniface O, Bernard O, Clerc F, Cartwright T, Alvarez F. Identification of the main epitope on human cytochrome P450 IID6 recognized by anti-liver kidney microsome antibody. J Immunol 1991;4:607-15.
120. Todros L, Touscoz G, D'Urso N, Durazzo M, Albano E, Poli G et al. Hepatitis C virus-related chronic liver disease with autoantibodies to liver-kidney microsomes (LKM). Clinical characterization from idiopathic LKM-positive disorders. J Hepatol 1991;13:128-31.
121. Lunel F, Abuaf N, Frangeul L, Grippon P, Perrin M, Le Coz Y et al. Liver/kidney microsome antibody type 1 and hepatitis C virus infection. Hepatology 1992;16:630-6.
122. Durazzo M, Philipp T, van Pelt FN, Luttig B, Borghesio E, Michel G et al. Heterogeneity of microsomal autoantibodies (LKM) in chronic hepatitis C and D virus infection. Gastroenterology 1995;108:455-62.
123. Choudhuri K, Gregorio GV, Mieli-Vergani G, Vergani D. Immunological cross-reactivity to multiple autoantigens in patients with liver kidney microsomal type 1 autoimmune hepatitis. Hepatology 1998;28:1177-81.
124. Dalekos GN, Wedemeyer H, Obermayer-Straub P, Kayser A, Barut A, Frank H et al. Epitope mapping of cytochrome P4502D6 autoantigen in patients with chronic hepatitis C during alpha-interferon treatment. J Hepatol 1999;30:366-75.
125. 193-212: a new immunodominant epitope and target of virus/self cross-reactivity in liver kidney microsomal autoantibody type 1-positive liver disease. J Immunol 2003:170:1481-9.
126. Marceau G, Lapierre P, Beland K, Soudeyns H, Alvarez F. LKM1 autoantibodies in chronic hepatitis C infection: a case of molecular mimicry? Hepatology 2005;42:675-82.
127. Bogdanos DP, Lenzi M, Okamoto M, Riggopoulou EI, Muratori P, Ma Y et al. Multiple viral/self immunological cross-reactivity in liver kidney microsomal antibody positive hepatitis C virus infected patients associated with the possession of HLA B51. Int J Immunopathol Pharmacol 2004;17:83-92.
128. Czaja AJ, Manns MP, Homburger HA. Frequency and significance of antibodies to liver/kidney microsome type 1 in adults with chronic active hepatitis. Gastroenterology 1992;103:1290-5.
129. Reddy KR, Krawitt EL, Homberg JC, Jeffers LJ, de Medina M, Chastenay B et al. Absence of anti-LKM1 antibody in hepatitis C viral infection in the United States of America. J Viral Hepat 1995;2:175-9.
130. Michitaka K, Durazzo M, Tillmann HL, Walker D, Philipp T, Manns MP. Analysis of hepatitis C virus genome in patients with autoimmune hepatitis type 2. Gastroenterology 1994;106:1603-10.
131. Gerotto M, Pontisso P, Giostra F, Francesconi R, Muratori L, Ballardini G et al. Analysis of the hepatitis C virus genome in patients with anti-LKM-1 autoantibodies. J Hepatol 1994;21:273-6.
132. Czaja AJ, Kruger M, Santrach PJ, Moore SB, Manns MP. Genetic distinctions between types 1 and 2 autoimmune hepatitis. Am J Gastroenterol 1997;92: 2197-200.
133. Bittencourt PL, Goldberg AC, Cancado ELR, Porta G, Carrilho FJ, Farias AQ et al. Genetic heterogeneity in susceptibility to autoimmune hepatitis types 1 and 2. Am J Gastroenterol 1999;94:1906-13.
134. Djilali-Saiah I, Fakhfakh A, Louafi H, Caillat-Zucman S, Debray D, Alvarez F. HLA class II influences humoral autoimmunity in patients with type 2 autoimmune hepatitis. J Hepatol 2006;45:844-50.
135. Muratori P, Czaja AJ, Muratori L, Granito A, Pappas G, Cassani F et al. Evidence of a genetic basis for the different geographical occurrences of liver/kidney microsomal antibody type 1 in hepatitis C. Dig Dis Sci 2007;52:179-84.
136. Czaja AJ, Norman GL. Autoantibodies in the diagnosis and management of liver disease. J Clin Gastroenterol 2003;37:315-29.
137. Targan SR, Landers C, Vidrich A, Czaja AJ. High-titer antineutrophil cytoplasmic antibodies in type 1 autoimmune hepatitis. Gastroenterology 1995;108: 1159-66.
138. Zauli D, Ghetti S, Grassi A, Descovich C, Cassani F, Ballardini G et al. Anti-neutrophil cytoplasmic antibodies in type 1 and type 2 autoimmune hepatitis. Hepatology 1997;25:1105-7.
139. Terjung B, Herzog V, Worman HJ, Gestmann I, Bauer C, Sauerbruch T et al. Atypical antineutrophil cytoplasmic antibodies with perinuclear fluorescence in chronic inflammatory bowel diseases and hepatobiliary disorders colocalize with nuclear lamina proteins. Hepatology 1998;28:332-40.
140. Terjung B, Spengler U, Sauerbruch T, Woman HJ. "Atypical p-ANCA" in IBD and hepatobiliary disorders react with a 50-kilodalton nuclear envelope protein of neutrophils and myeloid cell lines. Gastroenterology 2000;119:310-22.
141. (Ser)Sec complex recognized by autoantibodies from patients with type 1 autoimmune hepatitis. Clin Exp Immunol 2000;121:364-74.
142. Baeres M, Herkel J, Czaja AJ, Wies I, Kanzler S, Cancado ELR et al. Establishment of standardized SLA/LP immunoassays: specificity for autoimmune hepatitis, worldwide occurrence, and clinical characteristics. Gut 2002;51:259-64.
143. (ser)sec/SLA/LP autoantibodies. Comparative study using in-house ELISA with a recombinant 48.8 kDa protein, immunoblot, and analysis of immunoprecipitated RNAs. Liver Int 2005;25:410-9.
144. Ma Y, Okamoto M, Thomas MG, Bogdanos DP, Lopes AR, Portmann B et al. Antibodies to conformational epitopes of soluble liver antigen define a severe form of autoimmune liver disease. Hepatology 2002;35:658-64.
145. Czaja AJ, Donaldson PT, Lohse AW. Antibodies to soluble liver antigen/liver pancreas and HLA risk factors in type 1 autoimmune hepatitis. Am J Gastroenterol 2002;97:413-9.
146. Czaja AJ, Shums Z, Norman GL. Frequency and significance of antibodies to soluble liver antigen/liver pancreas in variant autoimmune hepatitis. Autoimmunity 2002;35:475-83.
147. Czaja AJ, Shums Z, Norman GL. Nonstandard antibodies as prognostic markers in autoimmune hepatitis. Autoimmunity 2004;37:195-201.
148. Czaja AJ, Carpenter HA, Manns MP. Antibodies to soluble liver antigen, P450IID6, and mitochondrial complexes in chronic hepatitis. Gastroenterology 1993;105: 1522-8.
149. Kanzler S, Weidemann C, Gerken G, Lohr HF, Galle PR, Meyer zum Buschenfelde KH et al. Clinical significance of autoantibodies to soluble liver antigen in autoimmune hepatitis. J Hepatol 1999:31:635-40.
150. Spiess M. The asialoglycoprotein receptor: a model for endocytic transport receptors. Biochemistry 1990;29: 10009-22.
151. Hajoui O, Martin S, Alvarez F. Study of antigenic sites on the asialoglycoprotein receptor recognized by autoantibodies. Clin Exp Immunol 1998;113:339-45.
152. Schreiter T, Liu C, Gerken G, Treichel U. Detection of circulating autoantibodies directed against the asialoglycoprortein receptor using recombinant receptor subunit H1. J Immunol Methods 2005;301:1-10.
153. Treichel U, Poralla T, Hess G, Manns M, Meyer zum Buschefelde KH. Autoantibodies to human asialoglycoprotein receptor in autoimmune-type chronic hepatitis. Hepatology 1990;11:606-12.
154. Czaja AJ, Pfeifer KD, Decker RH, Vallari AS. Frequency and significance of antibodies to asialoglycoprotein receptor in type 1 autoimmune hepatitis. Dig Dis Sci 1996;41:1733-40.
155. McFarlane IG, Hegarty JE, McSorley CG, McFarlane BM, Williams R. Antibodies to liver-specific protein predict outcome of treatment withdrawal in autoimmune chronic active hepatitis. Lancet 1984;2:954-6.
156. Czaja AJ. The role of autoantibodies as diagnostic markers of autoimmune hepatitis. Expert Rev Clin Immunol 2006;2:33-48.
157. Chretien-Leprince P, Ballot E, Andre C, Olsson NO, Fabien N, Escande A et al. Diagnostic value of anti-F-actin antibodies in a French multicenter study. Ann NY Acad Sci 2005;1050:266-73.
158. Czaja AJ, Cassani F, Cataleta M, Valentini P, Bianchi FB. Frequency and significance of antibodies to actin in type 1 autoimmune hepatitis. Hepatology 1996;24: 1068-73.
159. Fusconi M, Cassani F, Zauli D, Lenzi M, Ballardini G, Volta U et al. Anti-actin antibodies: a new test for an old problem. J Immunol Methods 1990;130:1-8.
160. Cancado ELR, Vilas-Boas LS, Abrantes-Lemos CP, Novo NF, Porta G, Da Silva LC et al. Heat serum inactivation as a mandatory procedure for antiactin antibody detection in cell culture. Hepatology 1996;23:1098-104.
161. Cancado ELR, Abrantes-Lemos CP, Vilas-Boas LS, Novo NF, Carrilho FJ, Laudanna AA. Thermolabile and calcium-dependent serum factor interferes with polymerized actin, and impairs anti-actin antibody detection. J Immunol 2001;17:223-8.
162. Gueguen P, Dalekos G, Nousbaum JB, Zachou K, Putterman C, Youinou P et al. Double reactivity against actin and alpha-actinin defines a severe form of autoimmune hepatitis type 1. J Clin Immunol 2006;26: 495-505.
163. Granito A, Muratori L, Muratori P, Pappas G, Guidi M, Cassani F et al. Antibodies to filamentous actin (F-actin) in type 1 autoimmune hepatitis. J Clin Pathol 2006;59:280-4.
164. Martini E, Abuaf N, Cavalli F, Durand V, Johanet C, Homberg J-C. Antibody to liver cytosol (anti-LC1) in patients with autoimmune chronic active hepatitis type 2. Hepatology 1988;8:1662-6.
165. Abuaf N, Johanet C, Chretien P, Martini E, Soulier E, Laperche S et al. Characterization of the liver cytosol antigen type 1 reacting with autoantibodies in chronic active hepatitis. Hepatology 1992;16:892-8.
166. Muratori L, Cataleta M, Muratori P, Lenzi M, Bianchi FB. Liver/kidney microsomal antibody type 1 and liver cytosol antibody type 1 concentrations in type 2 autoimmune hepatitis. Gut 1998;42:721-6.
167. Han S, Tredger M, Gregorio GV, Mieli-Vergani G, Vergani D. Anti-liver cytosolic antigen type 1 (LC1) antibodies in childhood autoimmune liver disease. Hepatology 1995;21:58-62.
168. Bridoux-Henno L, Maggiore G, Johanet C, Fabre M, Vajro P, Dommergues JP et al. Features and outcome of autoimmune hepatitis type 2 presenting with isolated positivity for anti-liver cytosol antibody. Clin Gastroenterol Hepatol 2004;2:825-30.
169. Muratori L, Sztul E, Muratori P, Gao YS, Ripalti A, Ponti C et al. Distinct epitopes on formiminotransferase cyclodeaminase induce autoimmune liver cytosol antibody type 1. Hepatology 2001;34:494-501.
170. Renous R, Lapierre P, Djilali-Shah I, Vitozzi S, Alvarez F. Characterization of the antigenicity of the formiminotransferase-cyclodeaminase in type 2 autoimmune hepatitis. Exp Cell Res 2004;292:332-41.
171. Lapierre P, Djilali-Saiah I, Vitozzi S, Alvarez F. A murine model of type 2 autoimmune hepatitis: xenoimmunization with human antigens. Hepatology 2004;39: 1066-74.
172. Burlingame RW, Boey ML, Starkebaum G, Rubin RL. The central role of chromatin in autoimmune responses to histones and DNA in systemic lupus erythematosus. J Clin Invest 1994;94:184-92.
173. Li L, Chen M, Huang DY, Nishioka M. Frequency and significance of antibodies to chromatin in autoimmune hepatitis type 1. J Gastroenterol Hepatol 2000;15:1176-82.
174. Czaja AJ, Shums Z, Binder WL, Lewis SJ, Nelson VJ, Norman GL. Frequency and significance of antibodies to chromatin in autoimmune hepatitis. Dig Dis Sci 2003;48:1658-64.
175. Norman GL. Anti-Saccharomyces cerevisiae antibodies in inflammatory bowel disease. Clin Applied Immunol Rev 2001;2:45-63.
176. Muratori P, Muratori L, Guidi M, Maccariello S, Pappas G, Ferrari R et al. Anti-Saccharomyces cerevisiae antibodies (ASCA) and autoimmune liver diseases. Clin Exp Immunol 2003;132:473-6.
177. Czaja AJ, Shums Z, Donaldson PT, Norman GL. Frequency and significance of antibodies to Saccharomyces cerevisiae in autoimmune hepatitis. Dig Dis Sci 2004;49;611-8.
178. Fusconi M, Vannini A, Dall'Aglio AC, Pappas G, Cassani F, Ballardini G et al. Anti-cyclic citrullinated peptide antibodies in type 1 autoimmune hepatitis. Aliment Pharmacol Ther 2005;22:951-5.
179. Montano-Loza A, Czaja AJ, Carpenter HA, Piette A, Murphy D, Shums Z et al. Frequency and significance of antibodies to cyclic citrullinated peptide in type 1 autoimmune hepatitis. Autoimmunity 2006;39: 341-8.
180. Watanabe K, Akiyama K, Hikichi K, Ohtsuka R, Okuyama A, Senshu T. Combined biochemical and immunochemical comparison of peptidylarginine deiminases present in various tissues. Biochim Biophys Acta 1988;966:375-83.
181. Irigoyen P, Lee AT, Wener MH, Li W, Kern M, Batliwalla F et al. Regulation of anti-cyclic citrullinated peptide antibodies in rheumatoid arthritis. Contrasting effects of HLA-DR3 and the shared epitope alleles. Arthritis Rheum 2005;52:3813-8.
182. Ohana M, Okazaki K, Hajiro K, Uchida K. Antilactoferrin antibodies in autoimmune liver diseases. Am J Gastroenterol 1998;93:1334-9.
183. Vergani D, Alvarez F, Bianchi FB, Cancado ELR, Mackay IR, Manns MP et al. Liver autoimmune serology: a consensus statement from the committee for autoimmune serology of the International Hepatitis Group. J Hepatol 2004;41:677-83.
184. Czaja AJ, Hay JE, Rakela J. Clinical features and prognostic implications of severe corticosteroid-treated cryptogenic chronic active hepatitis. Mayo Clin Proc 1990;65:23-30.
185. Czaja AJ, Carpenter HA, Santrach PJ, Moore SB, Homburger HA. The nature and prognosis of severe cryptogenic chronic active hepatitis. Gastroenterology 1993;104:1755-61.
186. Czaja AJ, Manns MP. The validity and importance of subtypes of autoimmune hepatitis: a point of view. Am J Gastroenterol 1995;90:1206-11.
187. McFarlane IG. The relationship between autoimmune markers and different clinical syndromes in autoimmune hepatitis. Gut 1998;42:599-602.
188. McFarlane IG. Autoimmune hepatitis: clinical manifestations and diagnostic criteria. Can J Gastroenterol 2001;15:107-13.
189. McFarlane IG. Autoimmune hepatitis: diagnostic criteria, subclassifications, and clinical features. Clin Liver Dis 2002;6:605-21.
190. Homberg J-C, Abuaf N, Bernard O, Islam S, Alvarez F, Khalil SH et al. Chronic active hepatitis associated with antiliver/kidney microsome antibody type 1: a second type of "autoimmune" hepatitis. Hepatology 1987;7: 1333-9.
191. Lohr H, Manns M, Kyriatsoulis A, Lohse AW, Trautwein C, Meyer zum Buschenfelde KH et al. Clonal analysis of liver-infiltrating T cells in patients with LKM-1 antibody-positive autoimmune chronic active hepatitis. Clin Exp Immunol 1991;84:297-302.
192. Donaldson PT, Doherty DG, Hayllar KM, McFarlane IG, Johnson PJ, Williams R. Susceptibility to autoimmune chronic active hepatitis: human leukocyte antigens DR4 and A1-B8-DR3 are independent risk factors. Hepatology 1991;13:701-6.
193. Czaja AJ, Carpenter HA, Santrach PJ, Moore SB. Significance of HLA DR4 in type 1 autoimmune hepatitis. Gastroenterology 1993;105:1502-7.
194. Fainboim L, Marcos Y, Pando M, Capucchio M, Reyes GB, Galoppo C et al. Chronic active autoimmune hepatitis in children. Strong association with a particular HLA DR6 (DRB1*1301) haplotype. Hum Immunol 1994;41:146-50.
195. Pando M, Larriba J, Fernandez GC, Fainboim H, Ciocca M, Ramonet M et al. Pediatric and adult forms of type 1 autoimmune hepatitis in Argentina: evidence for differential genetic predisposition. Hepatology 1999;30: 1374-80.
196. Goldberg AC, Bittencourt PL, Mougin B, Cancado ELR, Porta G, Carrilho F et al. Analysis of HLA haplotypes in autoimmune hepatitis type 1: identifying the major susceptibility locus. Hum Immunol 2001;62:165-9.
197. Czaja AJ, Carpenter HA, Moore SB. Clinical and HLA phenotypes of type 1 autoimmune hepatitis in North America outside DR3 and DR4. Liver Int 2006;26: 552-8.
198. Czaja AJ, Carpenter HA, Moore SB. HLA DRBl*13 as a risk factor for type 1 autoimmune hepatitis in North American patients. Dig Dis Sci. In press.
199. Czaja AJ, Strettell MDJ, Thomson LJ, Santrach PJ, Moore SB, Donaldson PT et al. Associations between alleles of the major histocompatibility complex and type 1 autoimmune hepatitis. Hepatology 1997;25:317-23.
200. Fainboim L, Velasco VCC, Marcos CY, Ciocca M, Roy A, Theiler G et al. Protracted, but not acute, hepatitis A virus infection is strongly associated with HLA-DRB1*1301, a marker for pediatric autoimmune hepatitis. Hepatology 2001;33:1512-7.
201. Vento S, Garofano T, Di Perri G, Dolci L, Concia E, Bassetti D. Identification of hepatitis A virus as a trigger for autoimmune chronic hepatitis type 1 in susceptible individuals. Lancet 1991;337:1183-7.
202. Huppertz HK, Treichel U, Gassel AM, Jeschke R, Meyer zum Buschenfelde KH. Autoimmune hepatitis following hepatitis A virus infection. J Hepatol 1995;23:204-8.
203. Tanaka H, Tujioka H, Ueda H, Hamagami H, Kida Y, Ichinose M. Autoimmune hepatitis triggered by acute hepatitis A. World J Gastroenterol 2005;11:6069-71.
204. Czaja AJ. Understanding the pathogenesis of autoimmune hepatitis. Am J Gastroenterol 2001;96:1224-31.
205. Vergani D, Choudhuri K, Bogdanos DP, Mieli-Vergani G. Pathogenesis of autoimmune hepatitis. Clin Liver Dis 2002;6:727-37.
206. Czaja AJ, Donaldson PT. Genetic susceptibilities for immune expression and liver cell injury in autoimmune hepatitis. Immunol Rev 2000;174:250-9.
207. Ichiki Y, Aoki CA, Bowlus CL, Shimoda S, Ishibashi H, Gershwin ME. T cell immunity in autoimmune hepatitis. Autoimmunity Rev 2005;4:315-21.
208. Doherty DG, Penzotti JE, Koelle DM, Kwok WW, Lybrand TP, Masewicz S et al. Structural basis of specificity and degeneracy of T cell recognition: pluriallelic restriction of T cell responses to a peptide antigen involves both specific and promiscuous interactions between the T cell receptor, peptide, and HLA-DR. J Immunol 1998;161:3527-35.
209. Manns MP, Obermayer-Straub P. Cytochromes P450 and uridine triphosphate-glucuronosyltransferases: model autoantigens to study drug-induced, virus-induced, and autoimmune liver disease. Hepatology 1997;26:1054-66.
210. Aguilera I, Wichmann I, Sousa JM, Bernardos A, Franco E, Garcia-Lozano R et al. Antibodies against glutathione S-transferase T1 (GSTT1) in patients with de novo immune hepatitis following liver transplantation. Clin Exp Immunol 2001;126:535-9.
211. Lapierre P, Hajoui O, Homberg J-C, Alvarez F. Formiminotransferase cyclodeaminase is an organ-specific autoantigen recognized by sera of patients with autoimmune hepatitis. Gastroenterology 1999;116:643-9.
212. Czaja AJ, Doherty DG, Donaldson PT. Genetic bases of autoimmune hepatitis. Dig Dis Sci 2002;47:2139-50.
213. Dessen A, Lawrence CM, Cupo S, Zaller DM, Wiley DC. X-ray crystal structure of HLA-DR4 (DRA*0101, DRB1*0401) complexed with a peptide from human collagen II. Immunity 1997;7:473-81.
214. Strettell MDJ, Donaldson PT, Thomson LJ, Santrach PJ, Moore SB, Czaja AJ et al. Allelic basis for HLA-encoded susceptibility to type 1 autoimmune hepatitis. Gastroenterology 1997;112:2028-35.
215. Doherty DG, Donaldson PT, Underhill JA, Farrant JM, Duthie A, Mieli-Vergani G et al. Allelic sequence variation in the HLA class II genes and proteins in patients with autoimmune hepatitis. Hepatology 1994;19:609-15.
216. Seki T, Ota M, Furuta S, Fukushima H, Kondo T, Hino K et al. HLA class II molecules and autoimmune hepatitis susceptibility in Japanese patients. Gastroenterology 1992;103:1041-7.
217. Yoshizawa K, Ota M, Katsuyama Y, Ichijo T, Matsumoto A, Tanaka E et al. Genetic analysis of the HLA region of Japanese patients with type 1 autoimmune hepatitis. J Hepatol 2005;42:578-84.
218. Vazquez-Garcia MN, Alaez C, Olivo A, Debaz H, Perez-Luque E, Burguete A et al. MHC class II sequences of susceptibility and protection in Mexicans with autoimmune hepatitis. J Hepatol 1998;28:985-90.
219. Qiu DK, Ma X. Relationship between human leukocyte antigen-DRB1 and autoimmune hepatitis type I in Chinese patients. J Gastroenterol Hepatol 2003;18: 63-7.
220. Donaldson PT, Czaja AJ. Genetic effects on susceptibility, clinical expression, and treatment outcome of type 1 autoimmune hepatitis. Clin Liver Dis 2002;6: 707-25.
221. Muratori P, Czaja AJ, Muratori L, Pappas G, Maccariello S, Cassani F et al. Genetic predispositions to autoimmune hepatitis in Italian and North American patients. World J Gastroenterol 2005;11:1862-6.
222. Montano-Loza A, Carpenter HA, Czaja AJ. Clinical significance of HLA DRB1*03-DRB1*04 in type 1 autoimmune hepatitis. Liver Int 2006;26:1201-8.
223. Agarwal K, Czaja AJ, Jones DEJ, Donaldson PT. CTLA-4 gene polymorphism and susceptibility to type 1 autoimmune hepatitis. Hepatology 2000;31:49-53.
224. Djilali-Saiah I, Ouellette P, Caillat-Zucman S, Debray D, Kohn JI, Alvarez F. CTLA-4/CD28 region polymorphisms in children from families with autoimmune hepatitis. Human Immunol 2001;62:1356-62.
225. Agarwal K, Jones DE, Daly AK, James OF, Vaidya B, Pearce S et al. CTLA-4 gene polymorphism confers susceptibility to primary biliary cirrhosis. J Hepatol 2000;32:538-41.
226. Vogel A, Strassburg CP, Manns MP. Genetic association of vitamin D receptor polymorphisms with primary biliary cirrhosis and autoimmune hepatitis. Hepatology 2002;35:126-31.
227. Fan L, Tu X, Zhu Y, Zhou L, Pfeiffer T, Feltens R et al. Genetic association of vitamin D receptor polymorphisms with autoimmune hepatitis and primary biliary cirrhosis in China. J Gastroenterol Hepatol 2005;20:249-55.
228. Vogel A, Strassburg CP, Manns MP. 77 C/G mutation in the tyrosine phosphatase CD45 gene and autoimmune hepatitis: evidence of a genetic link. Genes Immun 2003;4:79-81.
229. Esteghamat F, Noorinayer B, Sanati MH, Hekmatdoost A, Zafarghandi M, Shalmani HM et al. C77G mutation in protein tyrosine phosphatase CD45 gene and autoimmune hepatitis. Hepatol Res 2005;32:154-7.
230. Hirade A, Imazeki F, Yokosuka O, Kanda T, Kojima H, Fukai K et al. Fas polymorphisms influence susceptibility to autoimmune hepatitis. Am J Gastroenterol 2005;100:1322-9.
231. Agarwal K, Czaja AJ, Donaldson PT. A functional Fas promoter polymorphism is associated with a severe phenotype in type 1 autoimmune hepatitis characterized by early development of cirrhosis. Tissue Antigens. In press.
232. Fan L-Y Tu X-Q, Zhu Y, Pfeiffer T, Feltens R, Stoecker W et al. Genetic association of cytokine polymorphisms with autoimmune hepatitis and primary biliary cirrhosis in the Chinese. World J Gastroenterol 2005;11:2768-72.
233. Lapierre P, Beland K, Djilali-Saiah I, Alvarez F. Type 2 autoimmune hepatitis murine model: the influence of genetic background in disease development. J Autoimmun 2006;26:82-9.
234. Czaja AJ. Autoimmune hepatitis: evolving concepts and treatment strategies. Dig Dis Sci 1995;40:435-56.
235. Lohr HF, Schaak JF, Gerken G, Fleischer B, Dienes H-P, Meyer zum Buschenfelde KH. Phenotypical analysis and cytokine release of liver-infiltrating and peripheral blood T lymphocytes from patients with chronic hepatitis of different etiology. Liver 1994;14:161-6.
236. Czaja AJ, Sievers C, Zein NN. Nature and behavior of serum cytokines in type 1 autoimmune hepatitis. Dig Dis Sci 2000;45:1028-35.
237. Cookson S, Constantini PK, Clare M, Underhill JA, Bernal W, Czaja AJ et al. Frequency and nature of cytokine gene polymorphisms in type 1 autoimmune hepatitis. Hepatology 1999;30:851-6.
238. Czaja AJ, Cookson S, Constantini PK, Clare M, Underhill JA, Donaldson PT. Cytokine polymorphisms associated with clinical features and treatment outcome in type 1 autoimmune hepatitis. Gastroenterology 1999;117:645-52.
239. Bittencourt PL, Palacios SA, Cancado ELR, Porta G, Carrilho FJ, Laudanna AA et al. Cytotoxic T lymphocyte antigen-4 gene polymorphisms do not confer susceptibility to autoimmune hepatitis types 1 and 2 in Brazil. Am J Gastroenterol 2003;98:1616-20.
240. Longhi MS, Ma Y, Mitry RR, Bogdanos DP, Heneghan M, Cheeseman P et al. Effect of CD4+CD25+ regulatory T-cells on CD8 T-cell function in patients with autoimmune hepatitis. J Autoimmun 2005;25:63-71.
241. Longhi MS, Hussain MJ, Mitry RR, Arora SK, MieliVergani G, Vergani D et al. Functional study of CD4+CD25+ regulatory T cells in health and autoimmune hepatitis. J Immunol 2006,176:4484-91.
242. Lan RY, Cheng C, Lian ZX, Tsuneyama K, Yang GX, Moritoki Y et al. Liver-targeted and peripheral blood alterations of regulatory T cells in primary biliary cirrhosis. Hepatology 2006;43:729-37.
243. Zhang C, Zhang J, Tian Z. The regulatory effect of natural killer cells: do "NK-reg cells" exist? Cell Mol Immunol 2006;3:241-54.
244. Tupin E, Kronenberg M. Activation of natural killer cell T cells by glycolipids. Methods Enzymol 2006;417:185-201.
245. Lalazar G, Preston S, Zigmond E, Ben Yaacov A, Ilan Y. Glycolipids as immune modulatory tools. Mini Rev Med Chem 2006;6:1249-53.
246. Takeda K, Hayakawa Y, Van Kaer L, Matsuda H, Yagita H, Okumura K. Critical contribution of liver natural killer T cells to a murine model of hepatitis. Proc Natl Acad Sci USA 2000;97:5498-503.
247. Takahashi H, Oikawa T, Amano K, Tamaki S, Kuniyasu Y, Hokari A et al. Intrahepatic NKT cell and soluble CD1d have a significant role in the immuno-pathogenesis of AIH but not in PBC. Hepatology 2006;44 Suppl 1:227A-8A.
248. Fox CK, Furtwaengler A, Nepomuceno RR, Martinez OM, Krams SM. Apoptotic pathways in primary biliary cirrhosis and autoimmune hepatitis. Liver 2001;21: 272-9.
249. Rust C, Gores GJ. Apoptosis and liver disease. Am J Med 2000;108:567-74.
250. Bai J, Odin JA. Apoptosis and the liver: relation to autoimmunity and other conditions. Autoimmun Rev 2003;2:36-42.
251. Ogawa S, Sakaguchi K, Takaki A, Shiraga K, Sawayama T, Mouri H et al. Increase in CD95 (Fas/APO-1)-positive CD4+ and CD8+ T cells in peripheral blood derived from patients with autoimmune hepatitis or chronic hepatitis C with autoimmune phenomena. J Gastroenterol Hepatol 2000;15: 69-75.
252. Czaja AJ, Santrach PJ, Moore SB. Shared genetic risk factors in autoimmune liver disease. Dig Dis Sci 2001;46:140-7.
253. Alarcon-Segovia D. Shared autoimmunity: a concept for which the time has come. Autoimmunity 2005;38: 201-3.
254. Cook GC, Mulligan R, Sherlock S. Controlled prospective trial of corticosteroid therapy in active chronic hepatitis. Q J Med 1971;40:159-85.
255. Soloway RD, Summerskill WHJ, Baggenstoss AH, Geall MG, Gitnick GL, Elveback LR et al. Clinical, biochemical, and histological remission of severe chronic active liver disease: a controlled study of treatments and early prognosis. Gastroenterology 1972;63:820-33.
256. Murray-Lyon IM, Stern RB, Williams R. Controlled trial of prednisone and azathioprine in active chronic hepatitis. Lancet 1973;1:735-7.
257. Vierling JM, Flores PA. Evolving new therapies of autoimmune hepatitis. Clin Liver Dis 2002;6:825-50.
258. Czaja AJ. Treatment strategies in autoimmune hepatitis. Clin Liver Dis 2002;6:799-824.
259. Verma S, Gunuwan B, Mendler M, Govindrajan S, Redeker A. Factors predicting relapse and poor outcome in type 1 autoimmune hepatitis: role of cirrhosis development, patterns of transaminases during remission, and plasma cell activity in the liver biopsy. Am J Gastroenterol 2004;99:1510-6.
260. Miyake Y, Iwasaki Y, Terada R, Takagi S, Okamoto R, Ikeda H et al. Persistent normalization of serum alanine aminotransferase levels improves the prognosis of type 1 autoimmune hepatitis. J Hepatol 2005;43:951-7.
261. Montano-Loza AJ, Carpenter HA, Czaja AJ. Improving the end point of corticosteroid therapy in type 1 autoimmune hepatitis to reduce the frequency of relapse. Am J Gastroenterol. In press.
262. Montano-Loza AJ, Carpenter HA, Czaja AJ. Consequences of treatment withdrawal in type 1 autoimmune hepatitis. Liver Int. In press.
263. Czaja AJ, Menon KVN, Carpenter HA. Sustained remission after corticosteroid therapy for type 1 autoimmune hepatitis: a retrospective analysis. Hepatology 2002;35:890-7.
264. Lebovics E, Schaffner F, Klion EM, Simon C. Autoimmune chronic active hepatitis in postmenopausal women. Dig Dis Sci 1985;30:824-8.
265. Wang KK, Czaja AJ. Prognosis of corticosteroid-treated hepatitis B surface antigen-negative chronic active hepatitis in postmenopausal women: a retrospective analysis. Gastroenterology 1989;97:1288-93.
266. Uribe M, Go VLW, Kluge D. Prednisone for chronic active hepatitis: pharmacokinetics and serum binding in patients with chronic active hepatitis and steroid major side effects. J Clin Gastroenterol 1984;6:331-5.
267. Jeurissen MEC, Boerbooms AM, Van De Putte LBA. Pancytopenia related to azathioprine in rheumatoid arthritis. Ann Rheum Dis 1988;47:503-5.
268. Maddocks JL, Lennard L, Amess J, Amor R, Meyrick Thomas R. Azathioprine and severe bone marrow depression. Lancet 1986;1:156.
269. Ben Ari Ziv, Mehta A, Lennard L, Burroughs AK. Azathioprine-induced myelosuppression due to thiopurine methyltransferase deficiency in a patient with autoimmune hepatitis. J Hepatol 1995;23:351-4.
270. Langley PG, Underhill J, Tredger JM, Norris S, McFarlane IG. Thiopurine methyltransferase phenotype and genotype in relation to azathioprine therapy in autoimmune hepatitis. J Hepatol 2002;37:441-7.
271. Czaja AJ, Carpenter HA. Thiopurine methyltransferase deficiency and azathioprine intolerance in autoimmune hepatitis. Dig Dis Sci 2006;51:968-75.
272. Heneghan MA, Allan ML, Bornstein JD, Muir AJ, Tendler DA. Utility of thiopurine methyltransferase genotyping and phenotyping, and measurement of azathioprine metabolites in the management of patients with autoimmune hepatitis. J Hepatol 2006;45:584-91.
273. Gisbert JP, Gonzalez-Guijarro L, Cara C, Pajares JM, Moreno-Otero R. Thiopurine methyltransferase activity in patients with autoimmune hepatitis. Med Clin (Barc) 2003;121:481-4.
274. Sogo T, Fujisawa T, Inui A, Komatsu H, Etani Y, Tajiri H et al. Intravenous methylprednisolone pulse therapy for children with autoimmune hepatitis. Hepatol Res 2006;34:187-92.
275. Debray D, Maggiore G, Girardet JP, Mallet E, Bernard O. Efficacy of cyclosporin A in children with type 2 autoimmune hepatitis. J Pediatr 1999;135:111-4.
276. Alvarez F, Ciocca M, Canero-Velasco C, Ramonet M, de Davila MT, Cuarterolo M et al. Short-term cyclosporine induces a remission of autoimmune hepatitis in children. J Hepatol 1999;30:222-7.
277. Jackson LD, Song E. Cyclosporin in the treatment of corticosteroid resistant autoimmune chronic active hepatitis. Gut 1995;36:459-61.
278. Person JL, McHutchison JG, Fong TL, Redeker AG. A case of cyclosporine-sensitive, steroid resistant, autoimmune chronic active hepatitis. J Clin Gastroenterol 1993;17:317-20.
279. Sherman KE, Narkewicz M, Pinto PC. Cyclosporine in the management of corticosteroid-resistant type 1 autoimmune chronic active hepatitis. J Hepatol 1994;21:1040-7.
280. Fernandes NF, Redeker AG, Vierling JM, Villamil FG, Fong TL. Cyclosporine therapy in patients with steroid resistant autoimmune hepatitis. Am J Gastroenterol 1999;94:241-8.
281. Malekzadeh R, Nasser-Moghaddam S, Kaviani MJ, Taheri H, Kamalian N, Sotoudeh M. Cyclosporin-A is a promising alternative to corticosteroids in autoimmune hepatitis. Dig Dis Sci 2001;46:1321-7.
282. Van Thiel DH, Wright H, Carroll P, Abu-Elmagd K, Rodriguez-Rilo H, McMichael J et al. Tacrolimus: a potential new treatment for autoimmune chronic active hepatitis: results of an open-label preliminary trial. Am J Gastroenterol 1995;90:771-6.
283. Aqel BA, Machicao V, Rosser B, Satyanarayana R, Harnois DM, Dickson RC. Efficacy of tacrolimus in the treatment of steroid refractory autoimmune hepatitis. J Clin Gastroenterol 2004;38:805-9.
284. Richardson PD, James PD, Ryder SD. Mycophenolate mofetil for maintenance of remission in autoimmune hepatitis patients resistant to or intolerant of azathioprine. J Hepatol 2000;33:371-5.
285. Devlin SM, Swain MG, Urbanski SJ, Burak KW. Mycophenolate mofetil for the treatment of autoimmune hepatitis in patients refractory to standard therapy. Can J Gastroenterol 2004;18:321-6.
286. Chatur N, Ramji A, Bain VG, Ma MM, Marotta PJ, Ghent CN et al. Transplant immunosuppressive agents in non-transplant chronic autoimmune hepatitis: the Canadian association for the study of liver (CASL) experience with mycophenolate mofetil and tacrolimus. Liver Int 2005;25:723-7.
287. Czaja AJ, Carpenter HA. Empiric therapy of autoimmune hepatitis with mycophenolate mofetil: comparison with conventional treatment for refractory disease. J Clin Gastroenterol 2005;39:819-25.
288. Clissold SP, Heel RC. Budesonide: a preliminary review of its pharmacodynamic properties and therapeutic efficacy in asthma and rhinitis. Drugs 1984;28:485-518.
289. Danielsson A, Prytz H. Oral budesonide for treatment of autoimmune chronic active hepatitis. Aliment Pharmacol Ther 1994;8:585-90.
290. Wiegand J, Schuller A, Kanzler S, Lohse A, Beuers U, Kreisel W et al. Budesonide in previously untreated autoimmune hepatitis. Liver Int 2005;25:927-34.
291. Csepregi A, Rocken C, Treiber G, Malfertheiner P. Budesonide induces complete remission in autoimmune hepatitis. World J Gastroenterol 2006;12: 1362-6.
292. Czaja AJ, Lindor KD. Failure of budesonide in a pilot study of treatment-dependent autoimmune hepatitis. Gastroenterology 2000;119:1312-6.
293. Geier A, Gartung C, Dietrich CG, Wasmuth HE, Reinartz P, Matern S. Side effects of busdesonide in liver cirrhosis due to chronic autoimmune hepatitis: influence of hepatic metabolism versus portosystemic shunts on a patient complicated with HCC. World J Gastroenterol 2003;9:2681-5.
294. de Boer NKH, van Nieuwkerk CMJ, Pages MNA, de Boer SY, Derijks LJJ, Mulder CJJ. Promising treatment of autoimmune hepatitis with 6-thioguanine after adverse events on azathioprine. Eur J Gastroenterol 2005;17:457-61.
295. de Boer NKH, De Graaf P, Wilhelm AJ, Mulder CJJ, Van Bodegraven AA. On the limitation of 6-tioguaninenucleotide monitoring during tioguanine treatment. Aliment Pharmacol Ther 2005;22:447-51.
296. Santos ES, Arosemena LR, Raez LE, O'Brien C, Regev A. Successful treatment of autoimmune hepatitis and idiopathic thrombocytopenic purpura with the monoclonal antibody, rituximab: case report and review of the literature. Liver Int 2006;26:625-9.
297. Geramno V, Picchianti Diamanti A, Baccano G, Natale E, Onetto Muda A et al. Autoimmune hepatitis associated with infliximab in a patient with psoriatic arthritis. Ann Rheum Dis 2005;64:1519-20.
298. Tobon GJ, Canas C, Jaller JJ, Restrepo JC, Anaya JM. Serious liver disease induced by infliximab. Clin Rheumatol. In press.
299. Naveau S, Chollet-Martin S, Dharancy S, Mathurin P, Jouet P, Piquet MA et al. A double-blind randomized controlled trial of infliximab associated with prednisolone in acute alcoholic hepatitis. Hepatology 2004;39:1390-7.
300. Kanzler S, Gerken G, Dienes HP, Meyer zum Buschenfelde KH, Lohse AW. Cyclophosphamide as alternative immunosuppressive therapy for autoimmune hepatitis - report of three cases. Z Gastroenterol 1997;35:571-8.
301. Burak KW, Urbanski SJ, Swain MG. Successful treatment of refractory type 1 autoimmune hepatitis with methotrexate. J Hepatol 1998;29:990-3.
302. Rebollo Bernardez J, Cifuentes Mimoso C, Pinar Moreno A, Caunedo Alvarez A, Salas Herrero E, Jimenez-Saenz M et al. Deflazacort for long-term maintenance of remission in type 1 autoimmune hepatitis. Rev Esp Enferm Dig 1999;91:630-8.
303. Carmassi F, Morale R, Puccetti R, Pistelli F, Palla R, Bevilacqua G et al. Efficacy of intravenous immunoglobulin therapy in a case of autoimmune-mediated chronic active hepatitis. Clin Exp Rheumatol 1992;10: 13-7.
304. Swada K, Ohnishi K, Kosaka T, Chikano S, Egashira A, Okui M et al. Exacerbated autoimmune hepatitis successfully treated with leukocytapheresis and bilirubin adsorption therapy. J Gastroenterol 1997;32: 689-95.
305. Fridkis-Hareli M, Rosloniec EF, Fugger L, Strominger JL. Synthetic peptides that inhibit binding of the collagen type II 261-273 epitope to rheumatoid arthritis-associated HLA-DR1 and -DR4 molecules and collagen-specific T-cell responses. Hum Immunol 2000;61:640-50.
306. Guinan EC, Boussiotis VA, Neuberg D, Brennan LL, Hirano N, Nadler LM et al. Transplantation of anergic histoincompatible bone marrow allografts. N Engl J Med 1999;340:1704-14.
307. Wardrop RM, Whitacre CC. Oral tolerance in the treatment of inflammatory autoimmune diseases. Inflamm Res 1999;48:106-19.
308. Lohse AW, Dienes HP, Meyer zum Buschenfelde KH. Suppression of murine experimental autoimmune hepatitis by T-cell vaccination or immunosuppression. Hepatology 1998;27:1536-43.
309. Nelson DR, Lauwers GY, Lau JY, Davis GL. Interleukin 10 treatment reduces fibrosis in patients with chronic hepatitis C: a pilot study of interferon nonresponders. Gastroenterology 2000;118:655-60.
310. Menon KV, Stadheim L, Kamath PS, Wiesner RH, Gores GJ, Peine CJ et al. A pilot study of the safety and tolerability of etanercept in patients with alcoholic hepatitis. Am J Gastroenterol 2004;99:255-60.
311. Hannon GJ, Rossi JJ. Unlocking the potential of the human genome with RNA interference. Nature 2004;431:371-8.
312. Song E, Lee S-K, Wang J, Ince N, Ouyang N, Min J et al. RNA interference targeting Fas protects mice from fulminant hepatitis. Nat Med 2003;9:347-51.
313. Touhy VK, Mathisen PM. Gene therapy for autoimmune diseases. In: Manns MP, Paumgartner G, Leuschner U, editors. Immunology and Liver, Falk Symposium 114. Dordrecht: Kluwer Academic Publishers, BV; 2000. p. 376-85.
314. Vierling J. Autoimmune liver disease. Action Plan for Liver Disease Research. National Institute of Diabetes and Digestive and Liver Diseases, 2004. http://www.niddk.nih.gov/fund/divisions/ddn/ldrb/top_ics.htm.